Ensign Peak Advisors
MRNA icon

Ensign Peak Advisors’s Moderna MRNA Stock Holding History

Ensign Peak Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
17,000
-12,307
-42% -$637K ﹤0.01% 820
2026
Q1 		$1.49M Buy
29,307
+11,107
+61% +$518K ﹤0.01% 767
2025
Q4 		$537K Sell
18,200
-105,975
-85% -$2.88M ﹤0.01% 944
2025
Q3 		$3.21M Buy
124,175
+295
+0.2% +$8.23K 0.01% 688
2025
Q2 		$3.42M Buy
123,880
+29,265
+31% +$771K 0.01% 732
2025
Q1 		$2.68M Buy
94,615
+26,796
+40% +$951K 0.01% 804
2024
Q4 		$2.82M Sell
67,819
-770
-1% -$36.8K 0.01% 809
2024
Q3 		$4.58M Sell
68,589
-4,475
-6% -$411K 0.01% 648
2024
Q2 		$8.68M Sell
73,064
-80,198
-52% -$10.1M 0.02% 483
2024
Q1 		$16.3M Buy
153,262
+56,350
+58% +$5.68M 0.03% 359
2023
Q4 		$9.64M Buy
96,912
+14,735
+18% +$1.24M 0.02% 449
2023
Q3 		$8.49M Buy
82,177
+40,185
+96% +$4.48M 0.02% 432
2023
Q2 		$5.1M Sell
41,992
-107,060
-72% -$14.3M 0.01% 582
2023
Q1 		$22.9M Buy
149,052
+29,110
+24% +$4.8M 0.05% 265
2022
Q4 		$21.5M Buy
119,942
+63,368
+112% +$10.4M 0.05% 283
2022
Q3 		$6.69M Sell
56,574
-44,905
-44% -$6.81M 0.02% 459
2022
Q2 		$14.5M Buy
101,479
+4,870
+5% +$696K 0.03% 314
2022
Q1 		$16.6M Buy
96,609
+54,600
+130% +$9.19M 0.03% 324
2021
Q4 		$10.7M Sell
42,009
-37,848
-47% -$11.1M 0.02% 456
2021
Q3 		$30.7M Buy
79,857
+65,392
+452% +$24.1M 0.06% 240
2021
Q2 		$3.4M Sell
14,465
-13,845
-49% -$2.47M 0.01% 817
2021
Q1 		$3.71M Sell
28,310
-5,237
-16% -$759K 0.01% 764
2020
Q4 		$3.5M Sell
33,547
-42,148
-56% -$4.26M 0.01% 758
2020
Q3 		$5.36M Buy
75,695
+18,375
+32% +$1.28M 0.01% 612
2020
Q2 		$3.68M Buy
+57,320
New +$3.14M 0.01% 705

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Ensign Peak Advisors's MRNA Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Moderna (MRNA) stake by 42% in Q2 2026, selling an estimated $637K and leaving 17,000 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #820.

Ensign Peak Advisors first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $30.7M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ensign Peak Advisors held 17,000 shares of Moderna worth $1.19M as of Q2 2026.
  • Ensign Peak Advisors sold 12,307 Moderna shares in Q2 2026, an estimated $637K.
  • Moderna made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #820 holding.
  • Ensign Peak Advisors first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Ensign Peak Advisors's Moderna position peaked at $30.7M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.